EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants

Miyu Moriyama, Carolina Lucas, Valter Silva Monteiro iD, Yale SARS-CoV-2 Genomic Surveillance Initiative, Akiko Iwasaki iD

Proceedings of the National Academy of Sciences · 2023

DOI: 10.1073/pnas.2221652120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2023. Verfasst von Miyu Moriyama und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Howard Hughes Medical Institute, HHS | NIH | National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) possess mutations that confer resistance to neutralizing antibodies within the Spike protein and are associated with breakthrough infection and reinfection. By contrast, less is known about the escape from CD8+ T cell-mediated immunity by VOC. Here, we demonstrated that all SARS-CoV-2 VOCs possess the ability to suppress major histocompatibility complex class I (MHC-I) expression. We identified several viral genes that contribute to the suppression of MHC I expression. Notably, MHC-I upregulation was strongly inhibited after SARS-CoV-2 but not influenza virus infection in vivo. While earlier VOCs possess similar capacity as the ancestral strain to suppress MHC-I, the Omicron subvariants exhibited a greater ability to suppress surface MHC-I expression. We identified a common mutation in the E protein of Omicron that further suppressed MHC-I expression. Collectively, our data suggest that in addition to escaping from neutralizing antibodies, the success of Omicron subvariants to cause breakthrough infection and reinfection may in part be due to its optimized evasion from T cell recognition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2HumansAntibodies, NeutralizingAntibodies, ViralBreakthrough InfectionsReinfectionSpike Glycoprotein, Coronavirus

Stichwörter der Autor:innen

CD8 T cellCOVID-19MHCcytotoxic T lymphocytesviral evasion

Substanzen

Antibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520.
  • Department of Molecular Cellular and Developmental Biology, Yale University, New Haven CT 06520.
  • HHMI, Chevy Chase, MD 20815.

ORCID-Profile: Valter Silva Monteiro, Akiko Iwasaki

Förderung

  • NIAID NIH HHS
  • Howard Hughes Medical Institute
  • HHS | NIH | National Institute of Allergy and Infectious Diseases

Zitieren

APA

Moriyama, M., Lucas, C., Monteiro, V. S., Yale SARS-CoV-2 Genomic Surveillance Initiative, & Iwasaki, A. (2023). Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2221652120

Vancouver

Moriyama M, Lucas C, Monteiro VS, Yale SARS-CoV-2 Genomic Surveillance Initiative, Iwasaki A. Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2221652120

BibTeX
@article{Moriyama2023,
  author = {Moriyama, Miyu and Lucas, Carolina and Monteiro, Valter Silva and Yale SARS-CoV-2 Genomic Surveillance Initiative, Yale SARS-CoV-2 Genomic Surveillance Initiative and Iwasaki, Akiko},
  title = {Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2023},
  doi = {10.1073/pnas.2221652120}
}
Kostenlos starten →